Lucia Masarova, MD, of the University of Texas MD Anderson Cancer Center, discusses a study that indirectly compared the safety of momelotinib and fedratinib in patients with myelofibrosis.
Dr. Masarova and colleagues presented results from the matching-adjusted indirect comparison during the 2023 American Society of Clinical Oncology Annual Meeting.
The study analyzed safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Momelotinib showed a “favorable safety profile” over fedratinib in patients with and without previous Janus kinase inhibitor exposure, Dr. Masarova and colleagues found. The risk of hematologic adverse events, diarrhea, and nausea over 24 weeks was significantly lower with momelotinib than fedratinib.